Aequus Pharmaceuticals Inc. (CVE:AQS – Get Free Report) shares hit a new 52-week low on Monday . The stock traded as low as C$0.01 and last traded at C$0.01, with a volume of 3905 shares. The stock had previously closed at C$0.02.
Aequus Pharmaceuticals Price Performance
The stock’s fifty day moving average price is C$0.01 and its 200-day moving average price is C$0.02. The company has a quick ratio of 0.46, a current ratio of 0.07 and a debt-to-equity ratio of 138.88. The company has a market capitalization of C$1.99 million, a price-to-earnings ratio of -1.50 and a beta of -0.02.
Aequus Pharmaceuticals (CVE:AQS – Get Free Report) last issued its earnings results on Thursday, August 29th. The company reported C($0.01) EPS for the quarter. The firm had revenue of C$0.16 million during the quarter. On average, sell-side analysts predict that Aequus Pharmaceuticals Inc. will post -0.1 earnings per share for the current fiscal year.
About Aequus Pharmaceuticals
Aequus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease.
Featured Articles
- Five stocks we like better than Aequus Pharmaceuticals
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- 2 Chip Stocks Benefitting from OpenAI’s Chip Strategy Expansion
- How to buy stock: A step-by-step guide for beginners
- Monday.com’s Manic Price Pullback Is a Signal to Buy
- Investing in Travel Stocks Benefits
- 3 “Made in America” Stocks to Benefit From the Trump Presidency
Receive News & Ratings for Aequus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aequus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
